Pawlenty and ‘who’s who’ of retail pharmacy headline 13th annual Issues Summit
NEW YORK — CVS/pharmacy. Rite Aid. Walgreens. Sam’s Club. Ahold. H-E-B. The Katz Group. Giant Eagle. Good Neighbor. Health Mart. The list of participating companies in the 13th Annual Drug Store News Group Industry Issues conference — which will be held Tuesday, Nov. 29, here at the highly prestigious New York Athletic Club — reads like a “who’s who” of pharmacy retailing. And so, too, does the list of guest moderators who will lead the programs for the multiple panel discussions that will occur that day:
Issues Summit: Championing both points of view, respectively, will be retailer and vendor veterans Dave Van Howe (formerly of Walgreens, CVS and Arbor Drug), Market Performance Group VP and general manager; and Dan Mack (formerly of Dentek, GoJo and GlaxoSmithKline), EVP strategic business development at Swanson Group/Elevation Forum. They will focus on two key topics — health and wellness, and product innovation.
Health, Wellness & Technology Summit: Moderated by longtime pharmacy vet Bob Dufour (formerly Walmart director of pharmacy services and government relations), this special closed-door session (sponsors only) will examine new and emerging technology solutions will drive health, wellness and patient care.
Specialty Pharmacy Leadership Summit: Moderated by another longtime pharmacy vet Dave Fong (formerly of Safeway and Longs Drug), this panel, which includes representatives from leading specialty pharmacy providers Walgreens, Diplomat, BioPlus, SXC and others, will examine the high-growth, high-touch, high-cost specialty pharmacy and biotech market, fueled by its ever-expanding product pipeline and complicated by ever-changing protocols and shifting economics.
Diabetes Leadership Forum: Moderated by Dave Wendland, VP of Hamacher Resource Group, this panel will examine best practices among suppliers and retailers in trying to improve health outcomes and maximize opportunities to engage one of the most critical pharmacy customers.
Special guest, former two-term Minnesota governor and GOP hopeful Tim Pawlenty will deliver the lunchtime keynote address, handicapping the field of potential Republican nominees for 2012, and sharing his views on the current political climate, including what America needs to do about health reform, taxes, education, the economy and the deficit.
To register for the 2012 DSN Industry Issues Summit, visit DSNIndustryIssues.com. Sponsors include: Armada Health Care, Catalina Marketing, Emdeon, Endo Pharmaceuticals, GlaxoSmithKline Consumer Healthcare, Hylands, Kay Naturals, Koldkeepers, Kony, Moonshado, Novartis, Novo Nordisk, Numera Social, Pacific World, Pfizer Consumer Healthcare, Pharmavite, SoloHealth, Surveyor Health, Tabs Group, Takeda and Ultimed.
Appeals court rejects Teva request to stop Watson from selling generic Seasonique
PARSIPPANY, N.J. — An appeals court has thrown out an attempt by Teva Pharmaceutical Industries to stop Watson Pharmaceuticals from selling a generic contraceptive, Watson said.
The U.S. Court of Appeals for the Federal Circuit affirmed a lower court’s June 16 decision to deny Duramed Pharmaceuticals’ request for an injunction that would stop Watson from selling a generic version of Seasonique (levonorgestrel and ethinyl estradiol [0.15 mg/0.03 mg] and ethinyl estradiol [0.01 mg]). Duramed originally was a subsidiary of Barr Pharmaceuticals, which Teva acquired in 2008.
Watson launched its version of Seasonique, sold under the brand name Amethia, in July.
Watson files for approval of generic dementia treatment
PARSIPPANY, N.J. — Watson Pharmaceuticals is challenging three of Swiss drug maker Novartis’ patents on a drug used to treat dementia, Watson said.
The company said subsidiary Watson Labs had filed for approval generic rivastigmine transdermal system patches in the 4.6-mg and 9.5-mg strengths, both designed to last for 24 hours, with the Food and Drug Administration. The patches are used to treat mild to moderate dementia associated with Alzheimer’s or Parkinson’s disease.
The drug is a generic version of Novartis’ Exelon, which had sales of about $424 million during the 12-month period ended in September, according to IMS Health. Novartis responded by filing a patent-infringement suit against Watson on Wednesday in the U.S. District Court for the District of Delaware in order to prevent Watson from commercializing the patches before the expirations of three patents, which are set to occur in 2014 and 2019, according to FDA records.